Uygun Kazim, Aydiner Adnan, Saip Pinar, Kocak Zafer, Basaran Mert, Dincer Maktav, Topuz Erkan
Department of Oncology, University of Trakya, Edirne, Turkey.
Gynecol Oncol. 2003 Mar;88(3):400-3. doi: 10.1016/s0090-8258(02)00141-5.
The objectives of this study were to evaluate the patients' characteristics and treatment results for 11 recurrent granulosa cell tumors (GCT) of the ovary.
Tumor registries were screened retrospectively for all patients treated between 1979 and 1999 for ovarian tumors at the University of Istanbul. All information about these patients was obtained from operation, pathology, and follow-up reports. Then the clinical data were extracted. The patients were classified in stages according to FIGO criteria. There were 952 ovarian carcinomas, of which 45 were GCT. Eleven of 45 patients (24%) developed recurrent disease on follow-up.
All patients but one had advanced (III-IV) disease at diagnosis. The median progression-free interval (PFI) was 16 months (range, 5-39 months) with a marked difference in PFI between patients receiving (24 months) and not receiving (8 months) initial chemotherapy. Among patients received chemotherapy (six patients), two complete and two partial responses were observed, for an overall response rate of 67%. The median survival for all patients was 26 (4-73) months with a longer survival (38 versus 8 months) for patients retreated with a platinum-containing regimen.
Despite the fact that small number of treated cases does not allow an adequate evaluation, retreatment with cis-platinum-containing regimens may be the treatment of choice for patients with recurrent disease.
本研究旨在评估11例复发性卵巢颗粒细胞瘤（GCT）患者的特征及治疗结果。
对伊斯坦布尔大学1979年至1999年间治疗的所有卵巢肿瘤患者的肿瘤登记资料进行回顾性筛查。有关这些患者的所有信息均来自手术、病理及随访报告。然后提取临床数据。根据国际妇产科联盟（FIGO）标准对患者进行分期。共有952例卵巢癌患者，其中45例为GCT。45例患者中有11例（24%）在随访中出现复发性疾病。
除1例患者外，所有患者在诊断时均为晚期（III-IV期）疾病。无进展生存期（PFI）的中位数为16个月（范围5-39个月），接受初始化疗（24个月）和未接受初始化疗（8个月）的患者之间PFI有显著差异。在接受化疗的患者（6例）中，观察到2例完全缓解和2例部分缓解，总缓解率为67%。所有患者的中位生存期为26（4-73）个月，接受含铂方案再次治疗的患者生存期更长（38个月对8个月）。
尽管治疗病例数较少，无法进行充分评估，但含顺铂方案再次治疗可能是复发性疾病患者的首选治疗方法。
